ArticleFrontiers in oncology2024

Vδ2 T-cell engagers bivalent for Vδ2-TCR binding provide anti-tumor immunity and support robust Vγ9Vδ2 T-cell expansion.

Lisa A King et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.